Press Releases

Date Title  
07/29/21
Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
aPROMISE was developed to quantify and standardize assessment of PSMA PET/CT images and will support PYLARIFY ® (piflufolastat F 18) adoption in the U.S. NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 29, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ) announced today that its
07/28/21
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
Worldwide revenue of $101.1 million for the second quarter 2021, representing an increase of 53.1% from the prior year period GAAP net loss of $26.7 million for the second quarter 2021, compared to GAAP net loss of $7.0 million in the prior year period GAAP fully diluted net loss of $0.39 for the
07/14/21
Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 14, 2021-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 2021 , to discuss its financial and operating results for the second quarter of
06/14/21
Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 14, 2021-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow
05/27/21
Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
PYLARIFY will be available immediately to imaging centers in parts of the mid- Atlantic and southern regions and is expected to be broadly available throughout the U.S. by year end NORTH BILLERICA, Mass. --(BUSINESS WIRE)--May 27, 2021-- Lantheus Holdings, Inc.
05/21/21
Lantheus Holdings Announces Presentation Featuring ¹⁸F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--May 21, 2021-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious
05/20/21
Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--May 20, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical
05/04/21
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
Worldwide revenue of $92.5 million for the first quarter 2021, representing an increase of 2.0% from the prior year period Net income of $9.0 million for the first quarter 2021, compared to net income of $3.3 million in the prior year period GAAP fully diluted EPS of $0.13 for the first quarter
05/03/21
EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--May 3, 2021-- EXINI Diagnostics AB , a subsidiary of Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence (AI) solutions
04/30/21
Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 30, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical
04/20/21
Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 20, 2021-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021 , to discuss its financial and operating results for the first quarter of 2021.
04/07/21
Lantheus Expands R&D Leadership Team with Key New Hires
Bela Denes , MD Joins as Vice President of Medical Affairs Iryna Teslenko , MD, MBA Joins as Vice President of Clinical Development NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 7, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of
04/01/21
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
Names Daniel Niedzwiecki as Senior Vice President and General Counsel NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 1, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and
03/30/21
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 30, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical
03/22/21
Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021
- Statistically Significant Correlation Between Biomarker Responses and Objective Tumor Response - NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 22, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics,
03/01/21
Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies
OSPREY Phase 2/3 Results Published in the Journal of Urology   CONDOR Phase 3 Results Published in Clinical Cancer Research NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 1, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative
02/25/21
Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results
Worldwide revenue of $94.2 million and $339.4 million for the fourth quarter and full year 2020, representing an increase of 5.4% and a decline of 2.3% over the prior year period, respectively Net loss of $3.4 million and $13.5 million for the fourth quarter and full year 2020, compared to net
02/12/21
Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 12, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical
02/11/21
Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 11, 2021-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 4:30 p.m. ET on Thursday, February 25, 2021 , to discuss its financial and operating results for the fourth quarter and
02/04/21
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 4, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc. , and a global leader in the development, manufacture and commercialization of innovative
01/12/21
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
NORTH BILLERICA, Mass. --(BUSINESS WIRE)--Jan. 12, 2021-- Lantheus Holdings, Inc. (NASDAQ: LNTH) ( Lantheus ), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc. , and a global leader in the development, manufacture and commercialization of innovative